SAB Biotherapeutics, Inc. (SABS)

SAB Biotherapeutics Statistics

Total Valuation

SABS has a market cap or net worth of $12.73 million. The enterprise value is -$3.37 million.

Market Cap	12.73M
Enterprise Value	-3.37M

Important Dates

The next estimated earnings date is Monday, May 19, 2025, after market close.

Earnings Date	May 19, 2025
Ex-Dividend Date	n/a

Share Statistics

SABS has 9.29 million shares outstanding. The number of shares has increased by 67.74% in one year.

Current Share Class	9.29M
Shares Outstanding	9.29M
Shares Change (YoY)	+67.74%
Shares Change (QoQ)	+0.35%
Owned by Insiders (%)	20.27%
Owned by Institutions (%)	18.66%
Float	6.43M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.10
Forward PS	12.48
PB Ratio	0.46
P/TBV Ratio	0.49
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.98, with a Debt / Equity ratio of 0.18.

Current Ratio	2.98
Quick Ratio	2.61
Debt / Equity	0.18
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-134.77

Financial Efficiency

Return on equity (ROE) is -81.92% and return on invested capital (ROIC) is -57.16%.

Return on Equity (ROE)	-81.92%
Return on Assets (ROA)	-41.86%
Return on Invested Capital (ROIC)	-57.16%
Return on Capital Employed (ROCE)	-118.49%
Revenue Per Employee	$20,991
Profits Per Employee	-$541,354
Employee Count	63
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -68.79% in the last 52 weeks. The beta is 0.52, so SABS's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	-68.79%
50-Day Moving Average	1.54
200-Day Moving Average	2.67
Relative Strength Index (RSI)	46.90
Average Volume (20 Days)	25,615

Short Selling Information

The latest short interest is 92,667, so 1.00% of the outstanding shares have been sold short.

Short Interest	92,667
Short Previous Month	114,974
Short % of Shares Out	1.00%
Short % of Float	1.44%
Short Ratio (days to cover)	2.39

Income Statement

In the last 12 months, SABS had revenue of $1.32 million and -$34.11 million in losses. Loss per share was -$3.68.

Revenue	1.32M
Gross Profit	-28.93M
Operating Income	-42.91M
Pretax Income	-40.32M
Net Income	-34.11M
EBITDA	-38.20M
EBIT	-42.91M
Loss Per Share	-$3.68

Balance Sheet

The company has $20.76 million in cash and $4.67 million in debt, giving a net cash position of $16.09 million or $1.73 per share.

Cash & Cash Equivalents	20.76M
Total Debt	4.67M
Net Cash	16.09M
Net Cash Per Share	$1.73
Equity (Book Value)	25.97M
Book Value Per Share	2.80
Working Capital	15.81M

Cash Flow

In the last 12 months, operating cash flow was -$34.29 million and capital expenditures -$337,262, giving a free cash flow of -$34.63 million.

Operating Cash Flow	-34.29M
Capital Expenditures	-337,262
Free Cash Flow	-34.63M
FCF Per Share	-$3.73

Margins

Gross Margin	n/a
Operating Margin	-3,244.87%
Pretax Margin	-2,579.03%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

SABS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-67.74%
Shareholder Yield	-67.74%
Earnings Yield	-268.00%
FCF Yield	-272.12%

Analyst Forecast

The average price target for SABS is $11.40, which is 732.12% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.40
Price Target Difference	732.12%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	110.85%
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on January 5, 2024. It was a reverse split with a ratio of 0.1:1.

Last Split Date	Jan 5, 2024
Split Type	Reverse
Split Ratio	0.1:1

Scores

SABS has an Altman Z-Score of -5.53. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.53
Piotroski F-Score	n/a